Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""immunogenicity"" wg kryterium: Temat


Tytuł :
Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
Autorzy :
Schramm R; Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Costard-Jäckle A; Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany. .
Rivinius R; Klinik für Kardiologie, Angiologie Und Pneumologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg, Germany.
Fischer B; Institut für Transfusions- Und Labormedizin, Herz Und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Müller B; Institut für Transfusions- Und Labormedizin, Herz Und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Boeken U; Klinik für Herzchirurgie, Universitätsklinikum Düsseldorf, Heinrich Heine Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.
Haneya A; Klinik für Herznahe- und Gefäßchirurgie, Universitätsklinikum Schleswig-Holstein, Arnold-Heller-Str. 3, 24105, Kiel, Germany.
Provaznik Z; Klinik für Herz-, Thorax- Und Herznahe Gefäßchirurgie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Knabbe C; Institut für Transfusions- Und Labormedizin, Herz Und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Gummert J; Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Universitätsklinik, Ruhr-Universität Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany.
Pokaż więcej
Źródło :
Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2021 Aug; Vol. 110 (8), pp. 1142-1149. Date of Electronic Publication: 2021 Jul 09.
Typ publikacji :
Journal Article
MeSH Terms :
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Heart Transplantation/*adverse effects
Immunity, Cellular/*drug effects
Immunity, Humoral/*drug effects
Immunosuppressive Agents/*adverse effects
Lung Transplantation/*adverse effects
Adolescent ; Adult ; Aged ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; COVID-19/immunology ; COVID-19 Vaccines/adverse effects ; Case-Control Studies ; Female ; Heart-Lung Transplantation/adverse effects ; Humans ; Immunization Schedule ; Immunocompromised Host ; Immunosuppressive Agents/administration & dosage ; Male ; Middle Aged ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; Transplant Recipients ; Vaccination ; Young Adult
Czasopismo naukowe
Tytuł :
Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers.
Autorzy :
Kontopoulou K; Department of Microbiology, 'G. Gennimatas' General Hospital, Thessaloniki, Greece.
Ainatzoglou A; Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Ifantidou A; Department of Microbiology, 'G. Gennimatas' General Hospital, Thessaloniki, Greece.
Nakas CT; Laboratory of Biometry, University of Thessaly, Phytokou Str.38446, Nea Ionia/Volos, Magnesia, Greece.; University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Gkounti G; Department of Cardiology, 'G. Gennimatas' General Hospital, Thessaloniki, Greece.
Adamopoulos V; Department of Microbiology, 'G. Gennimatas' General Hospital, Thessaloniki, Greece.
Papadopoulos N; Department of Microbiology, 'G. Gennimatas' General Hospital, Thessaloniki, Greece.
Papazisis G; Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Clinical Trials Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Pokaż więcej
Źródło :
Journal of medical microbiology [J Med Microbiol] 2021 Aug; Vol. 70 (8).
Typ publikacji :
Journal Article
MeSH Terms :
Health Personnel*
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Adult ; Aged ; COVID-19/diagnosis ; COVID-19/virology ; COVID-19 Vaccines/administration & dosage ; Female ; Greece/epidemiology ; Humans ; Male ; Middle Aged ; Outcome Assessment, Health Care ; ROC Curve ; Vaccination ; Young Adult
Czasopismo naukowe
Tytuł :
Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
Autorzy :
Rozen-Zvi B; Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yahav D; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Infectious Diseases Unit, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel. Electronic address: .
Agur T; Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Zingerman B; Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ben-Zvi H; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Clinical Microbiology Laboratory, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel.
Atamna A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Infectious Diseases Unit, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel.
Tau N; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel.
Mashraki T; Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, Israel; Department of Transplantation, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel.
Nesher E; Department of Transplantation, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel.
Rahamimov R; Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Transplantation, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel.
Pokaż więcej
Źródło :
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2021 Aug; Vol. 27 (8), pp. 1173.e1-1173.e4. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Immunogenicity, Vaccine/*immunology
Kidney Transplantation/*adverse effects
RNA, Messenger/*immunology
SARS-CoV-2/*immunology
Adult ; Aged ; COVID-19/epidemiology ; COVID-19/virology ; COVID-19 Vaccines/genetics ; Cohort Studies ; Female ; Humans ; Immunity ; Immunogenicity, Vaccine/genetics ; Immunosuppression/adverse effects ; Male ; Middle Aged ; Prospective Studies ; RNA, Messenger/genetics ; SARS-CoV-2/genetics ; Transplant Recipients
Czasopismo naukowe
Tytuł :
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients.
Autorzy :
Havlin J; Prague Lung Transplant Program, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Svorcova M; Prague Lung Transplant Program, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Dvorackova E; Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
Lastovicka J; Department of Immunology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Lischke R; Prague Lung Transplant Program, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Kalina T; Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic. Electronic address: .
Hubacek P; Department of Medical Microbiology, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic.
Pokaż więcej
Źródło :
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [J Heart Lung Transplant] 2021 Aug; Vol. 40 (8), pp. 754-758. Date of Electronic Publication: 2021 May 21.
Typ publikacji :
Journal Article
MeSH Terms :
Immunogenicity, Vaccine*
Lung Transplantation*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Postoperative Complications/*prevention & control
Postoperative Complications/*virology
Antibody Formation ; Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
A self-assembling nanoparticle: Implications for the development of thermostable vaccine candidates.
Autorzy :
Liu ZH; Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: .
Xu HL; Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: .
Han GW; Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: .
Tao LN; Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: .
Lu Y; Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: .
Zheng SY; Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: .
Fang WH; Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou 310058, China. Electronic address: .
He F; Institute of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, Hangzhou 310058, China. Electronic address: .
Pokaż więcej
Źródło :
International journal of biological macromolecules [Int J Biol Macromol] 2021 Jul 31; Vol. 183, pp. 2162-2173. Date of Electronic Publication: 2021 Jun 05.
Typ publikacji :
Journal Article
MeSH Terms :
Immunogenicity, Vaccine*
Nanoparticles*
Antigens, Viral/*pharmacology
Classical Swine Fever/*prevention & control
Classical Swine Fever Virus/*immunology
Viral Vaccines/*pharmacology
Animals ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Antigens, Viral/genetics ; Antigens, Viral/immunology ; Cells, Cultured ; Classical Swine Fever/blood ; Classical Swine Fever/immunology ; Classical Swine Fever/virology ; Cytokines/metabolism ; Dendritic Cells/drug effects ; Dendritic Cells/immunology ; Dendritic Cells/metabolism ; Disease Models, Animal ; Drug Stability ; Female ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Recombinant Fusion Proteins/immunology ; Recombinant Fusion Proteins/pharmacology ; Swine ; Temperature ; Vaccines, Subunit/immunology ; Vaccines, Subunit/pharmacology ; Vaccines, Synthetic/immunology ; Vaccines, Synthetic/pharmacology ; Viral Vaccines/immunology
Czasopismo naukowe
Tytuł :
Evaluation of the immunogenicity and protective ability of a pili subunit, SBP2', of Streptococcus suis serotype 2.
Autorzy :
Guo G; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; Key Lab of Animal Bacteriology, Ministry of Agriculture, Nanjing 210095, China; OIE Reference Lab for Swine Streptococcosis, Nanjing 210095, China; MOE Joint International Research Laboratory of Animal Health and Food Safety, Nanjing, China. Electronic address: .
Kong X; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; Key Lab of Animal Bacteriology, Ministry of Agriculture, Nanjing 210095, China; OIE Reference Lab for Swine Streptococcosis, Nanjing 210095, China; MOE Joint International Research Laboratory of Animal Health and Food Safety, Nanjing, China.
Wang Z; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; Key Lab of Animal Bacteriology, Ministry of Agriculture, Nanjing 210095, China; OIE Reference Lab for Swine Streptococcosis, Nanjing 210095, China; MOE Joint International Research Laboratory of Animal Health and Food Safety, Nanjing, China.
Li M; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; Key Lab of Animal Bacteriology, Ministry of Agriculture, Nanjing 210095, China; OIE Reference Lab for Swine Streptococcosis, Nanjing 210095, China; MOE Joint International Research Laboratory of Animal Health and Food Safety, Nanjing, China.
Tan Z; NHC Key laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. Electronic address: .
Zhang W; College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China; Key Lab of Animal Bacteriology, Ministry of Agriculture, Nanjing 210095, China; OIE Reference Lab for Swine Streptococcosis, Nanjing 210095, China; MOE Joint International Research Laboratory of Animal Health and Food Safety, Nanjing, China. Electronic address: .
Pokaż więcej
Źródło :
Research in veterinary science [Res Vet Sci] 2021 Jul; Vol. 137, pp. 201-207. Date of Electronic Publication: 2021 May 14.
Typ publikacji :
Journal Article
MeSH Terms :
Immunogenicity, Vaccine*
Fimbriae, Bacterial/*immunology
Streptococcal Infections/*prevention & control
Streptococcal Vaccines/*immunology
Streptococcus suis/*immunology
Animals ; Escherichia coli/genetics ; Mice ; Mice, Inbred ICR ; Serogroup ; Streptococcal Infections/microbiology ; Streptococcus suis/genetics ; Vaccines, Synthetic/immunology
Czasopismo naukowe
Tytuł :
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
Autorzy :
Normark J; Umeå University, Umeå, Sweden.
Vikström L; Umeå University, Umeå, Sweden.
Gwon YD; Umeå University, Umeå, Sweden.
Persson IL; Umeå University, Umeå, Sweden.
Edin A; Umeå University, Umeå, Sweden.
Björsell T; Umeå University, Umeå, Sweden.
Dernstedt A; Umeå University, Umeå, Sweden.
Christ W; Karolinska Institutet, Stockholm, Sweden.
Tevell S; Region Värmland, Karlstad, Sweden.
Evander M; Umeå University, Umeå, Sweden.
Klingström J; Karolinska Institutet, Stockholm, Sweden.
Ahlm C; Umeå University, Umeå, Sweden .
Forsell M; Umeå University, Umeå, Sweden .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 09; Vol. 385 (11), pp. 1049-1051. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunization, Secondary*
Immunogenicity, Vaccine*
Antibodies, Neutralizing/*blood
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Adult ; Antibodies, Viral/blood ; COVID-19/immunology ; COVID-19 Vaccines/adverse effects ; Clinical Studies as Topic ; Humans ; Middle Aged
Raport
Tytuł :
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Autorzy :
Liu X; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Shaw RH; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Stuart ASV; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Greenland M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Andrews NJ; Statistics, Modelling and Economics Department, Public Health England, London, UK; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, UK.
Cameron JC; Health Protection Scotland, Glasgow, UK.
Charlton S; Public Health England, Porton Down, Salisbury, UK.
Clutterbuck EA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Collins AM; Liverpool School of Tropical Medicine, Liverpool, UK.
Dinesh T; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
England A; Public Health England, Porton Down, Salisbury, UK.
Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Ferreira DM; Liverpool School of Tropical Medicine, Liverpool, UK.
Finn A; School of Population Health Sciences and School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
Green CA; NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Hallis B; Public Health England, Porton Down, Salisbury, UK.
Heath PT; The Vaccine Institute, St George's University of London, London, UK.
Hill H; Liverpool School of Tropical Medicine, Liverpool, UK.
Lambe T; Jenner Institute, University of Oxford, Oxford, UK.
Lazarus R; North Bristol NHS Trust, Bristol, UK.
Libri V; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
Long F; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Mujadidi YF; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Plested EL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Provstgaard-Morys S; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Ramasamy MN; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Ramsay M; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, UK.
Read RC; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Singh N; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Turner DPJ; University of Nottingham, Nottingham, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK.
Turner PJ; National Heart and Lung Institute, Imperial College London, London, UK.
Walker LL; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
White R; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Nguyen-Van-Tam JS; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK.
Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: .
Pokaż więcej
Corporate Authors :
Com-COV Study Group
Źródło :
Lancet (London, England) [Lancet] 2021 Sep 04; Vol. 398 (10303), pp. 856-869. Date of Electronic Publication: 2021 Aug 06.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*adverse effects
COVID-19 Vaccines/*immunology
Aged ; Antibodies, Viral/blood ; COVID-19 Vaccines/administration & dosage ; Equivalence Trials as Topic ; Female ; Humans ; Immunization Schedule ; Immunoglobulin G/blood ; Intention to Treat Analysis ; Male ; Middle Aged ; Single-Blind Method ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Tytuł :
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.
Autorzy :
Jara A; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Undurraga EA; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
González C; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Paredes F; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Fontecilla T; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Jara G; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Pizarro A; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Acevedo J; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Leo K; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Leon F; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Sans C; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Leighton P; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Suárez P; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
García-Escorza H; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Araos R; From the Ministry of Health (A.J., C.G., F.P., T.F., G.J., A.P., J.A., K.L., F.L., C.S., P.L., P.S., H.G.-E., R.A.), Facultad de Matemáticas (A.J.) and Escuela de Gobierno (E.A.U.), Pontificia Universidad Católica de Chile, Millennium Nucleus Center for the Discovery of Structures in Complex Data (A.J.), Millennium Initiative for Collaborative Research in Bacterial Resistance (E.A.U., R.A.), the Research Center for Integrated Disaster Risk Management (E.A.U.), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo (R.A.), and the Advanced Center for Chronic Diseases (R.A.) - all in Santiago, Chile; and the CIFAR Azrieli Global Scholars Program, CIFAR, Toronto (E.A.U.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 02; Vol. 385 (10), pp. 875-884. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenicity, Vaccine*
Mass Vaccination*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/epidemiology ; COVID-19/mortality ; Chile/epidemiology ; Female ; Hospitalization/statistics & numerical data ; Humans ; Incidence ; Intensive Care Units ; Male ; Middle Aged ; Patient Acuity ; Prospective Studies ; Treatment Outcome ; Vaccines, Inactivated ; Young Adult
Czasopismo naukowe
Tytuł :
Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
Autorzy :
Wilder-Smith A; From the Institute of Social and Preventive Medicine, University of Bern, Switzerland (A.W.-S.); Murdoch Children's Research Institute, Melbourne, VIC, Australia (K.M.); and the London School of Hygiene and Tropical Medicine, London (K.M.).
Mulholland K; From the Institute of Social and Preventive Medicine, University of Bern, Switzerland (A.W.-S.); Murdoch Children's Research Institute, Melbourne, VIC, Australia (K.M.); and the London School of Hygiene and Tropical Medicine, London (K.M.).
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 02; Vol. 385 (10), pp. 946-948.
Typ publikacji :
Editorial
MeSH Terms :
Immunogenicity, Vaccine*
Mass Vaccination*
Vaccines, Inactivated*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
COVID-19/epidemiology ; Chile/epidemiology ; Disease Transmission, Infectious/prevention & control ; Hospitalization/statistics & numerical data ; Humans ; Incidence ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Autorzy :
Goepfert PA; Department of Medicine, University of Alabama at Birmingham, AL, USA.
Fu B; Sanofi Pasteur, Swiftwater, PA, USA.
Chabanon AL; Sanofi Pasteur, Lyon, France.
Bonaparte MI; Sanofi Pasteur, Swiftwater, PA, USA.
Davis MG; Rochester Clinical Research, Rochester, NY, USA.
Essink BJ; Meridian Clinical Research, Omaha, NE, USA.
Frank I; Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Haney O; Sanofi Pasteur, Swiftwater, PA, USA.
Janosczyk H; Sanofi Pasteur, Swiftwater, PA, USA.
Keefer MC; University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA.
Koutsoukos M; GlaxoSmithKline Vaccines, Wavre, Belgium.
Kimmel MA; Optimal Research, Melbourne, FL, USA.
Masotti R; Sanofi Pasteur, Swiftwater, PA, USA.
Savarino SJ; Sanofi Pasteur, Swiftwater, PA, USA.
Schuerman L; GlaxoSmithKline Vaccines, Wavre, Belgium.
Schwartz H; Research Centers of America, Hollywood, FL, USA.
Sher LD; Peninsula Research Associates, Rolling Hills Estates, CA, USA.
Smith J; Sanofi Pasteur, Swiftwater, PA, USA.
Tavares-Da-Silva F; GlaxoSmithKline Vaccines, Wavre, Belgium.
Gurunathan S; Sanofi Pasteur, Swiftwater, PA, USA.
DiazGranados CA; Sanofi Pasteur, Swiftwater, PA, USA.
de Bruyn G; Sanofi Pasteur, Swiftwater, PA, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Infectious diseases [Lancet Infect Dis] 2021 Sep; Vol. 21 (9), pp. 1257-1270. Date of Electronic Publication: 2021 Apr 19.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Immunogenicity, Vaccine*
Adjuvants, Immunologic/*administration & dosage
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Recombinant Proteins/*administration & dosage
SARS-CoV-2/*immunology
Adult ; Antibodies, Neutralizing/drug effects ; Antibodies, Viral/drug effects ; COVID-19 Vaccines/immunology ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Recombinant Proteins/immunology ; Spike Glycoprotein, Coronavirus ; United States/epidemiology
Czasopismo naukowe
Tytuł :
Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice.
Autorzy :
Stebbings R; AstraZeneca, Clinical Pharmacology & Safety Sciences, Melbourn Science Park, Melbourn, SG8 6HB, United Kingdom. Electronic address: .
Maguire S; AstraZeneca, Clinical Pharmacology & Safety Sciences, Melbourn Science Park, Melbourn, SG8 6HB, United Kingdom.
Armour G; AstraZeneca, Clinical Pharmacology & Safety Sciences, Melbourn Science Park, Melbourn, SG8 6HB, United Kingdom.
Jones C; AstraZeneca, Clinical Pharmacology & Safety Sciences, Granta Park, Cambridge, CB21 6GP, United Kingdom.
Goodman J; AstraZeneca, Clinical Pharmacology & Safety Sciences, Granta Park, Cambridge, CB21 6GP, United Kingdom.
Maguire AK; AstraZeneca, Clinical Pharmacology & Safety Sciences, Melbourn Science Park, Melbourn, SG8 6HB, United Kingdom.
Tang CM; AstraZeneca, Clinical Pharmacology & Safety Sciences, Granta Park, Cambridge, CB21 6GP, United Kingdom.
Skellett V; AstraZeneca, Clinical Pharmacology & Safety Sciences, Granta Park, Cambridge, CB21 6GP, United Kingdom.
Harris J; AstraZeneca, Clinical Pharmacology & Safety Sciences, Melbourn Science Park, Melbourn, SG8 6HB, United Kingdom.
Pokaż więcej
Źródło :
Reproductive toxicology (Elmsford, N.Y.) [Reprod Toxicol] 2021 Sep; Vol. 104, pp. 134-142. Date of Electronic Publication: 2021 Jul 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Immunogenicity, Vaccine*
Vaccination*
Antibodies, Viral/*blood
COVID-19 Vaccines/*administration & dosage
Animals ; Biomarkers/blood ; COVID-19 Vaccines/toxicity ; Female ; Fetus/drug effects ; Fetus/immunology ; Fetus/metabolism ; Gestational Age ; Lactation/immunology ; Lactation/metabolism ; Maternal-Fetal Exchange ; Mice ; Placenta/immunology ; Placenta/metabolism ; Pregnancy ; Prenatal Exposure Delayed Effects ; Risk Assessment ; Seroconversion
Czasopismo naukowe
Tytuł :
Paucisymptomatic COVID-19 in lung transplant recipient following two doses of mRNA-1273 (Moderna) vaccine.
Autorzy :
Marinelli T; Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
Chaparro C; Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
Humar A; Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
Kumar D; Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada. Electronic address: .
Pokaż więcej
Źródło :
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [J Heart Lung Transplant] 2021 Sep; Vol. 40 (9), pp. 1019. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
COVID-19 Vaccines*
Immunogenicity, Vaccine*
Lung Transplantation*
COVID-19/*diagnosis
COVID-19/*prevention & control
Lung Diseases/*surgery
COVID-19/complications ; Female ; Humans ; Lung Diseases/etiology ; Lung Diseases/immunology ; Middle Aged
Raport
Tytuł :
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.
Autorzy :
Hagin D; Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: .
Freund T; Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Navon M; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Halperin T; Laboratory for HIV Diagnosis, the AIDS Center, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Adir D; Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Marom R; Laboratory for HIV Diagnosis, the AIDS Center, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Levi I; Laboratory for HIV Diagnosis, the AIDS Center, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Benor S; Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Alcalay Y; Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Freund NT; Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: .
Pokaż więcej
Źródło :
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2021 Sep; Vol. 148 (3), pp. 739-749. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Primary Immunodeficiency Diseases/*complications
Adult ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19/etiology ; COVID-19/virology ; Disease Susceptibility ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Immunity, Cellular ; Male ; Middle Aged ; Primary Immunodeficiency Diseases/genetics ; SARS-CoV-2/immunology ; Young Adult
Czasopismo naukowe
Tytuł :
Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.
Autorzy :
van Doremalen N; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Fischer RJ; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Schulz JE; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Holbrook MG; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Smith BJ; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Lovaglio J; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Petsch B; CureVac AG, 72076 Tuebingen, Germany.
Munster VJ; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Pokaż więcej
Źródło :
Viruses [Viruses] 2021 Aug 19; Vol. 13 (8). Date of Electronic Publication: 2021 Aug 19.
Typ publikacji :
Journal Article; Research Support, N.I.H., Intramural
MeSH Terms :
Immunization, Secondary*
Immunogenicity, Vaccine*
Antibodies, Viral/*blood
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Vaccines, Synthetic/*immunology
Animals ; Antibodies, Neutralizing/blood ; COVID-19 Vaccines/administration & dosage ; Immunity, Cellular ; Immunization Schedule ; Macaca mulatta ; Male ; Spike Glycoprotein, Coronavirus/immunology ; T-Lymphocytes/immunology ; Vaccines, Synthetic/administration & dosage
Czasopismo naukowe
Tytuł :
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
Autorzy :
Lopez Bernal J; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Andrews N; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Gower C; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Gallagher E; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Simmons R; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Thelwall S; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Stowe J; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Tessier E; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Groves N; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Dabrera G; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Myers R; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Campbell CNJ; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Amirthalingam G; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Edmunds M; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Zambon M; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Brown KE; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Hopkins S; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Chand M; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Ramsay M; From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Aug 12; Vol. 385 (7), pp. 585-594. Date of Electronic Publication: 2021 Jul 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenicity, Vaccine*
SARS-CoV-2*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/epidemiology ; COVID-19/virology ; Case-Control Studies ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome ; United Kingdom/epidemiology ; Vaccine Potency ; Young Adult
SCR Organism :
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł :
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
Autorzy :
Edara VV; Emory University School of Medicine, Atlanta, GA.
Pinsky BA; Stanford University School of Medicine, Stanford, CA.
Suthar MS; Emory University School of Medicine, Atlanta, GA .
Lai L; Emory University School of Medicine, Atlanta, GA .
Davis-Gardner ME; Emory University School of Medicine, Atlanta, GA .
Floyd K; Emory University School of Medicine, Atlanta, GA .
Flowers MW; Emory University School of Medicine, Atlanta, GA .
Wrammert J; Emory University School of Medicine, Atlanta, GA .
Hussaini L; Emory University School of Medicine, Atlanta, GA .
Ciric CR; Emory University School of Medicine, Atlanta, GA .
Bechnak S; Emory University School of Medicine, Atlanta, GA .
Stephens K; Emory University School of Medicine, Atlanta, GA .
Graham BS; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Bayat Mokhtari E; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Mudvari P; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Boritz E; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Creanga A; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Pegu A; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Derrien-Colemyn A; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Henry AR; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Gagne M; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Douek DC; National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Sahoo MK; Stanford University School of Medicine, Stanford, CA.
Sibai M; Stanford University School of Medicine, Stanford, CA.
Solis D; Stanford University School of Medicine, Stanford, CA.
Webby RJ; St. Jude Children's Research Hospital, Memphis, TN.
Jeevan T; St. Jude Children's Research Hospital, Memphis, TN.
Fabrizio TP; St. Jude Children's Research Hospital, Memphis, TN.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Aug 12; Vol. 385 (7), pp. 664-666. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunogenicity, Vaccine*
Antibodies, Neutralizing/*blood
COVID-19/*immunology
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Antibodies, Viral/blood ; COVID-19/prevention & control ; Humans
SCR Organism :
SARS-CoV-2 variants
Raport
Tytuł :
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
Autorzy :
Kamar N; Toulouse University Hospital, Toulouse, France .
Abravanel F; Toulouse University Hospital, Toulouse, France .
Marion O; Toulouse University Hospital, Toulouse, France .
Couat C; Toulouse University Hospital, Toulouse, France .
Izopet J; Toulouse University Hospital, Toulouse, France .
Del Bello A; Toulouse University Hospital, Toulouse, France .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Aug 12; Vol. 385 (7), pp. 661-662. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji :
Letter
MeSH Terms :
Immunogenicity, Vaccine*
Transplant Recipients*
Antibodies, Viral/*blood
COVID-19/*immunology
COVID-19 Vaccines/*administration & dosage
SARS-CoV-2/*immunology
COVID-19/prevention & control ; Humans ; Vaccine Potency
Opinia redakcyjna
Tytuł :
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
Autorzy :
Malard F; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France. .; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France. .
Gaugler B; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Gozlan J; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.; APHP, Hôpital Saint Antoine, Department of Virology, Paris, France.
Bouquet L; Department of Medical Oncology, University Hospital of Besançon, INSERM, EFS BFC, UMR1098 RIGHT, Université de Bourgogne Franche-Comté, Besançon, France.
Fofana D; APHP, Hôpital Saint Antoine, Department of Virology, Paris, France.; Sorbonne Université Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM UMR S1136, Paris, France.
Siblany L; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Eshagh D; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Adotevi O; Department of Medical Oncology, University Hospital of Besançon, INSERM, EFS BFC, UMR1098 RIGHT, Université de Bourgogne Franche-Comté, Besançon, France.
Laheurte C; Department of Medical Oncology, University Hospital of Besançon, INSERM, EFS BFC, UMR1098 RIGHT, Université de Bourgogne Franche-Comté, Besançon, France.
Ricard L; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Dulery R; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Stocker N; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
van de Wyngaert Z; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Genthon A; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Banet A; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Memoli M; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.
Ikhlef S; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.
Sestilli S; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Vekhof A; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.
Brissot E; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Marjanovic Z; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.
Chantran Y; APHP, Hôpital Saint Antoine, Service d'Immunologie, Paris, France.
Cuervo N; APHP, Hôpital Saint Antoine, Department of Virology, Paris, France.
Ballot E; APHP, Hôpital Saint Antoine, Service d'Immunologie, Paris, France.
Morand-Joubert L; APHP, Hôpital Saint Antoine, Department of Virology, Paris, France.; Sorbonne Université Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM UMR S1136, Paris, France.
Mohty M; APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France.; Sorbonne Université, INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.
Pokaż więcej
Źródło :
Blood cancer journal [Blood Cancer J] 2021 Aug 10; Vol. 11 (8), pp. 142. Date of Electronic Publication: 2021 Aug 10.
Typ publikacji :
Journal Article
MeSH Terms :
Immunogenicity, Vaccine*
COVID-19/*complications
COVID-19/*immunology
COVID-19 Vaccines/*immunology
Hematologic Neoplasms/*complications
Hematologic Neoplasms/*immunology
SARS-CoV-2/*immunology
Adaptive Immunity ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19 Vaccines/administration & dosage ; Comorbidity ; Female ; Host-Pathogen Interactions/immunology ; Humans ; Immunoglobulin G/immunology ; Male ; Middle Aged ; Risk Factors ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Young Adult
Czasopismo naukowe
Tytuł :
Oldest Adults Need 2 mRNA Vaccine Doses to Neutralize SARS-CoV-2.
Autorzy :
Abbasi J
Pokaż więcej
Źródło :
JAMA [JAMA] 2021 Aug 10; Vol. 326 (6), pp. 473.
Typ publikacji :
Wiadomości
MeSH Terms :
Immunogenicity, Vaccine*
Antibodies, Neutralizing/*blood
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Adult ; Age Factors ; Aged, 80 and over ; COVID-19/immunology ; COVID-19 Vaccines/administration & dosage ; Humans ; SARS-CoV-2/immunology ; Vaccine Potency
SCR Organism :
SARS-CoV-2 variants
Periodyk

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies